Transition from Paris dosimetry system to 3D image-guided planning in interstitial breast brachytherapy

Judyta Wiercińska, MSc1,2, Anna Wronczewska, MD, PhD3, Renata Kabacińska, PhD4, Prof. Roman Makarewicz, MD2,3
1Medical Physics Department, Oncology Center, Bydgoszcz, 2Chair and Clinic of Oncology and Brachytherapy, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, Torun, 3Brachytherapy Department, Oncology Center, Bydgoszcz, Poland

Abstract

Purpose: The purpose of this study is to evaluate our first experience with 3D image-guided breast brachytherapy and to compare dose distribution parameters between Paris dosimetry system (PDS) and image-based plans.

Material and methods: First 49 breast cancer patients treated with 3D high-dose-rate interstitial brachytherapy as a boost were selected for the study. Every patient underwent computed tomography, and the planning target volume (PTV) and organs at risk (OAR) were outlined. Two treatment plans were created for every patient. First, based on a Paris dosimetry system (PDS), and the second one, imaged-based plan with graphical optimization (OPT). The reference isodose in PDS implants was 85%, whereas in OPT plans the isodose was chosen to obtain proper target coverage. Dose and volume parameters (D90, D100, V90, V100), doses at OARs, total reference air kerma (TRAK), and quality assurance parameters: dose nonuniformity ratio (DNR), dose homogeneity index (DHI), and conformity index (COIN) were used for a comparison of both plans.

Results: The mean number of catheters was 7 but the mean for 20 first patients was 5 and almost 9 for the next 29 patients. The mean value of prescribed isodose for OPT plans was 73%. The mean D90 was 88.2% and 105.8%, the D100 was 59.8% and 75.7%, the VPTV90 was 88.6% and 98.1%, the VPTV100 was 79.9% and 98.9%, and the TRAK was 0.00375 GYm–1 and 0.00439 GYm–1 for the PDS and OPT plans, respectively. The mean DNR was 0.29 and 0.42, the DHI was 0.71 and 0.58, and the COIN was 0.68 and 0.76, respectively.

Conclusions: The target coverage in image-guided plans (OPT) was significantly higher than in PDS plans but the dose homogeneity was worse. Also, the value of TRAK increased because of change of prescribing isodose. The learning curve slightly affected our results.

Key words: breast cancer, boost, image-based brachytherapy, Paris dosimetry.
3D imaging in currently available planning software’s gives us possibility to evaluate these parameters in clinical cases.

The purpose of this study is to analyze our first experience with 3D image-guided breast brachytherapy, compare dose distribution parameters between PDS, and image based treatment plans as well as to evaluate changes in planning procedure after implementing 3D system.

Material and methods

First, 49 consecutive patients during breast conserving therapy treated with 3D image-based high-dose-rate (HDR) interstitial brachytherapy as a boost after external beam radiotherapy were selected for the study. It was our first experience with planning based on computed tomography (CT), and the first couple of patients were implanted only based on surgery scar, clinical examination, and the results of mammography. Rest of them were implanted based on CT created for EBRT planning. Localization of tumor bed was done considering surgical clips. In our hospital, in majority of cases, only one surgery clip is placed on the muscle beneath the tumor bed. On this pre-planning CT we’ve measured distances in all three dimensions from surgery clips to distinctive elements of patient’s body, such as nipple, sternum, or rib. Then a printout containing 3D visualization of patient’s body with all these structures and measurements was prepared. Figure 1 presents an example of the printout. Distances from this visualization were measured on patient’s breast just before implantation to help localize lumpectomy cavity.

During the interstitial brachytherapy procedure, 4 to 13 metal needles in 1, 2 or 3 planes (2 patients – 1 plane, 31 patients – 2 planes, 16 patients – 3 planes) were inserted into tumor bed with template guidance. All patients underwent CT with a slice thickness of 2 mm. The CT images were sent to the brachytherapy planning system Oncentra Masterplan (version 4.3, Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden), where planning target volume (PTV) and OARs (skin, most exposed rib, ipsilateral lung) were contoured. Two treatment plans were made for every patient. First, based on PDS, using geometrical optimization, and the second one, image-based plan using graphical optimization (OPT). The reference isodose in PDS was 85% in every case, whereas in OPT plans an isodose was chosen to obtain proper target coverage. Dose and volume parameters ($D_{90}$, $D_{100}$, $V_{PTV90}$, $V_{PTV100}$), dose at OARs, total reference air kerma (TRAK), and quality assurance parameters: dose nonuniformity ratio (DNR), dose homogeneity index (DHI), and conformity index (COIN) were used for a comparison of both plans. The following definitions are used in our study [2]:

\[
DNR = \frac{V_{150}}{V_{100}}
\]

\[
DHI \text{ inside PTV} = \frac{V_{PTV150} - V_{PTV150}}{V_{PTV100}}
\]

\[
COIN = \frac{V_{PTV100}/V_{PTV}}{V_{PTV100}/V_{100}}
\]

Fig. 1. Printout of pre-planning procedure with ribs counted and numbered and distances marked in all three dimensions from surgery clips to distinctive elements of patient’s body (sternum and nipple)
where $V_{100}$ and $V_{200}$ means volume receiving 100% and 150% of prescribed dose, respectively, $V_{PTV100}$ and $V_{PTV150}$ means volume of PTV receiving 100% and 150% of prescribed dose, respectively, and $V_{PTV}$ means volume of PTV. Doses at OARs were evaluated by a dose at most exposed 0.1cc ($D_{0.1cc}$) and at the most exposed 2cc ($D_{2cc}$) of specific OAR. The second comparison was done to analyze a learning curve during our first experience with 3D image-guided planning. All plans (both PDS and OPT) were divided into two groups: group of the first 20 patients and group of the next 29 patients out of all 49 analyzed cases. The comparison was done between dose and volume parameters and quality assurance parameters of both groups. Calculations were performed with Statistica 8.0 (SPSS Inc., Chicago, IL, USA). A difference between two variables was considered statistically significant when the $p$-value was less than or equal to 0.05.

**Results**

One-, two-, and three-plane implants were used. The mean number of catheters was 7 but the mean for the first 20 patients was 5 and almost 9 for the remaining 29 patients. The volume of PTV ranged from 13.6 cm$^3$ to 163.4 cm$^3$ (mean: 58.2 cm$^3$), while the mean volume irradiated by prescribed dose was 53.0 cm$^3$ and 66.0 cm$^3$ for PDS and OPT plan, respectively. The mean value of isodose selected for prescribing dose for OPT plans was 73% in order to achieve acceptable dose coverage. The mean $D_{90}$ was 88.2% and 105.9%, the $D_{100}$ was 59.8% and 75.7%, the $V_{PTV90}$ was 88.6% and 98.1%, the $V_{PTV100}$ was 79.9% and 98.9%, and the TRAK was 0.00375 Gy$m^{-1}$ in these plans and amounted to 73.9% for skin $D_{0.1cc}$, 59.2% for skin $D_{2cc}$, 28.1% for the most exposed rib, and 73% in order to achieve acceptable dose coverage. The mean $D_{90}$ was 88.2% and 105.9%, the $D_{100}$ was 59.8% and 75.7%, the $V_{PTV90}$ was 88.6% and 98.1%, the $V_{PTV100}$ was 79.9% and 98.9%, and the TRAK was 0.00375 Gy$m^{-1}$ for PDS and OPT plans, respectively. Doses received by organs at risk were slightly higher in OPT plans because of lower value of prescribed isodose in these plans and amounted to 73.9% for skin $D_{90}$, 59.2% for skin $D_{2cc}$, 28.1% for the most exposed rib, and 21.0% for ipsilateral lung. The same doses for PDS plans amounted to 67.5% for skin $D_{90}$, 52.8% for skin $D_{2cc}$, 24.5% for the most exposed rib, and 18.1% for ipsilateral lung. All the doses are presented as a percentage of prescribed dose.

Better target coverage resulted also in worse homogeneity. We obtained mean DNR of 0.29 and 0.42, mean DHI inside PTV of 0.71, and 0.54 for PDS and OPT plans, respectively. Simultaneously, the optimization of a plan improved our conformity. Mean COIN for PDS plans was 0.69 while for OPT plans it was 0.76. A comparison was made between mean values of all doses and dosimetric parameters of both types of plan. Differences between all these parameters were statistically significant. Mean values of dosimetric parameters and doses at OARs of both plans are shown in Table 1.

| Dosimetric parameter | PDS plans | OPT plans | $p$ value |
|----------------------|-----------|-----------|-----------|
| $V_{PTV100}$ [%]     | 88.6 ± 7.0| 98.1 ± 2.4| < 0.05    |
| $V_{PTV200}$ [%]     | 79.9 ± 7.2| 93.9 ± 3.6| < 0.05    |
| $D_{90}$ [%]         | 88.2 ± 9.3| 105.9 ± 9.5< 0.05 |
| $D_{100}$ [%]        | 59.8 ± 9.4| 75.7 ± 5.4 |< 0.05    |
| Skin $D_{0.1cc}$ [%] | 67.5 ± 11.6| 73.9 ± 10.0< 0.05 |
| Skin $D_{2cc}$ [%]   | 52.8 ± 7.4| 59.2 ± 7.7 |< 0.05    |
| Rib $D_{0.1cc}$ [%]  | 24.5 ± 17.6| 28.1 ± 17.0< 0.05 |
| Lung $D_{2cc}$ [%]   | 18.1 ± 11.2| 21.0 ± 11.6< 0.05 |
| DNR                  | 0.29 ± 0.05| 0.42 ± 0.07< 0.05 |
| DHI inside PTV       | 0.71 ± 0.05| 0.54 ± 0.09 |< 0.05    |
| COIN                 | 0.69 ± 0.10| 0.76 ± 0.06< 0.05 |

$V_{PTV100}$ [%] – relative percentage of planning target volume, which receives 100% of prescribed dose, respectively; $D_{90}$ [%], $D_{100}$ [%] – dose to the 90% and 100% volume of interest relative to the prescribed dose, respectively. $D_{0.1cc}$, $D_{2cc}$ – dose at the most exposed 0.1cc and 2cc of volume of interest, respectively. DNR – dose nonuniformity ratio, DHI inside PTV – dose homogeneity index inside planning target volume, COIN – conformity index, TRAK [Gy$m^{-1}$] – total reference air kerma, PDS – Paris dosimetry system, OPT – image-based plan using graphical optimization.

| Dosimetric parameter | PDS plans | OPT plans |
|----------------------|-----------|-----------|
| First 20 patients    | Next 29 patients | First 20 patients | Next 29 patients |
| $V_{PTV100}$ [%]     | 79.5 | 80.3 | 93.5 | 94.2 |
| $D_{90}$ [%]         | 88.8 | 87.8 | 105.0 | 106.4 |
| $D_{100}$ [%]        | 62.0 | 58.3 | 76.7 | 76.0 |
| DNR                  | 0.33 | 0.26 | 0.44 | 0.4 |
| DHI inside PTV       | 0.68 | 0.74 | 0.54 | 0.55 |
| COIN                 | 0.69 | 0.67 | 0.75 | 0.76 |

$V_{PTV100}$ [%] – relative percentage of planning target volume, which receives 100% of prescribed dose, $D_{90}$, $D_{100}$ – dose at the 90% and 100% volume of interest relative to the prescribed dose, respectively, DNR – dose nonuniformity ratio, DHI inside PTV – dose homogeneity index inside planning target volume, COIN – conformity index, PDS – Paris dosimetry system, OPT – image-based plan using graphical optimization.
In our study, there was a high linear correlation between TRAKs and volume of PTV (PDS: $R = 0.97$ and OPT: $R = 0.98$), and also with number of needles (PDS: $R = 0.88$ and OPT: $R = 0.86$) for both types of plans. Figure 2 shows correlation between TRAKs and volume of PTV. There was also high linear correlation between TRAK and DHI in PDS plan ($R = 0.8$) but there were only very poor linear correlations between these parameters in OPT plans ($R = 0.1$), as well as between TRAK and the value of prescribed isodose - F-factor ($R = -0.21$). TRAK depends mostly on volume of PTV, while DHI and value of isodose chosen to obtain proper target coverage depends on implant quality. This results probably in such poor correlations between these factors. There were also high linear correlations between F-factor and DHI ($R = 0.76$) showed in Figure 3 but there was no linear correlation between F-factor and target coverage in OPT plans ($R = 0.1$).

**Discussion**

Paris dosimetry system has been successfully used for decades in interstitial brachytherapy due to its biggest advantage – homogenous dose distribution. In our study, we implemented standard PDS with geometrical optimization in plans made on CT’s and compared to second plans optimized to achieve proper target coverage. The target coverage in image-guided plans (OPT) was significantly higher than in plans based on PDS but the dose homogeneity was worse. Major et al. compared four different plans for interstitial breast brachytherapy [11]. One of them was based on the same principles as our PDS plan, that means standard PDS with geometrical optimization. They pointed high homogeneity of this type of plan with DNR of 0.25 and DHI inside PTV of 0.74. These values are almost the same as our results (0.29 and 0.71, respectively) but we received better target coverage and dose conformity: $D_{90}$ was 88% and 60%, and COIN 0.66 and 0.55 in our study and Major’s, respectively. In their another study, Major et al. used the same method of optimization as our OPT plans [12]. Their mean prescribed isodose was 74%, what is very similar to our 73%. They obtained homogeneity parameters slightly better than ours (mean DNR was 0.32 and mean DHI inside PTV was 0.66, compared to our 0.42 and 0.54, respectively) but they used pre- and postimplant CT, what probably resulted in better implant. Aristei et al. also used preimplant CT and obtained excellent results of mean $D_{90}$ – 96.5% and DHI for the whole implant of 0.76 [13]. Vicini et al. analyzed non-CT-based implantation with geometrical optimized plan and they obtained worse target coverage but very high homogeneity with mean values of $D_{90}$, $D_{100}$, and DHI for whole implant, respectively, 73%, 68%, and 0.89 for five selected patients (from 8 selected for the study) [14]. Kestin et al. analyzed retrospectively a group of 11 patients and showed that even slight dwell time adjustment could result in better target coverage from 85.3% to
97.0% for lumpectomy cavity, while keeping D90 on high level of 0.86 (0.89 before adjustment) [15]. In their study, there was no information about improvement of coverage of entire target volume (cavity with 1 cm margin). Das et al. obtained excellent results of median D100 of 96% and mean D90 of 0.73 using geometrical and graphical optimization in CT-based plans [16] but it has to be added that they identified PTV by injecting contrast material inside lumpectomy cavity and used preimplant mammography. Wazer et al. showed that high values of dose homogeneity index reduce risk of late fibrosis, so it is very important to improve homogeneity while keeping good target coverage and conformity of our plans [17]. Major et al. found high improvement of their results after using preimplant CT (VPTV100 from 70% to 91%, DNR from 0.35 to 0.33 and COIN from 0.40 to 0.68) [11, 18]. Cholewka et al. came to the same conclusion after comparing their 2D plans without pre-planning to CT based guided plans [19]. They obtained an improvement of VPTV100 from 86.1% to 91.7% and dose homogeneity index from 0.53 to 0.60. The same trend could be seen in our study when comparing our first 20 patients implanted mostly basing on surgical scar and clinical examination with the next 29 with pre-planning based on CT scans. We’ve noticed an increase of VPTV100 from 93.5% to 94.2% and dose homogeneity index from 0.56 to 0.60 for the whole implant, and from 0.54 to 0.55 for PTV only. It means that further improvements of implant quality could be achieved during the implantation of needles. Tang et al. analyzed impact of implantation method on the implant quality comparing free hand technique under ultrasound guidance with template method based on CT images with radiographic contrast injected into tumor bed before needles insertion [20]. They obtained excellent dose homogeneity index for both methods (0.74 for free hand and 0.76 for template technique), with significantly better target coverage and less high doses volumes for insertion with template guidance. There is a number of studies focused on the impact of different image-based pre-planning methods on treatment plan quality [1, 2, 4, 5, 6, 20, 21, 22, 23]. All of them confirmed that before implantation as much information as possible should be included to precisely localize the tumor bed. Slight improvement of our dosimetric parameters could also result from a learning curve. It’s too small group and too short period of time to make a reliable evaluation, but a trend could be seen when comparing groups of the first 20 and the next 29 patients. Cholewka et al. analyzed their learning curve in first experiences with 3D image-based brachytherapy [24]. They’ve noticed a gentle progress every 6 months during the whole 4 years of observation. The scale of their improvement is similar to our results when comparing the same period of time.

There are very few studies containing information about values of TRAK in breast brachytherapy planning, even it is recommended for reporting in every brachytherapy application by ESTRO [25]. We consider TRAK as very valuable factor, especially in case of transition from standard 2D planning to 3D image-based method. In our study, we noticed 16% increase of TRAK from 0.0038 GYm⁻¹ for standard Paris system based planning to 0.0044 GYm⁻¹ for 3D planning. The reason for that is the lower prescription isodose line what increases irradiated volume. In both types of our planning methods, values of TRAK were highly correlated with volume of PTV as evident from the Graph 1. Major et al. noted the same correlation in their study [18]. Contemporary standards of brachytherapy planning are image-based and all recommendations emphasized that 3D imaging is crucial to receive proper target coverage [26, 27]. However, long-term studies proved good results after BCS obtained with boost based on PDS. Retrospectives studies provided by Resch et al. on large cohort of 410 women with early stage breast cancer after BCT with interstitial brachytherapy boost showed excellent results with only 16 recurrences (2 and 3.9% in 5-year and 10-year actuarial recurrence rate), and only 7% of cosmetic outcomes classified as bad [28]. Similar results were obtained by Polgar et al. with 7% ipsilateral breast failure after median follow-up time of 94 months on cohort of 100 patients [29]. It will take time to collect as many reliable image-guided long-term studies as 2D-based ones available at present.

**Conclusion**

Our first experience with 3D image-based planning showed that optimized plans based on CT could significantly improve target coverage and dose conformity but only at the cost of worse dose homogeneity compared to plans based on principles of PDS. We’ve observed a learning curve during implantation as well as in treatment planning procedure. Implementation of 3D imaging in pre-planning procedure could result in further improvements of implant quality and allow to obtain satisfactory dosimetric parameters.

**Disclosure**

Authors report no conflict of interest.

**References**

1. Nag S, Kuske R, Vicini F et al. Brachytherapy in treatment of breast cancer. Oncology(Williston Park) 2001; 15: 195-202.
2. Strnad V, Potter R, Kovacs G. Practical Handbook of Brachytherapy. UNI-MED, Verlag AG, Bremen 2014.
3. Mould RF, Battermann JJ, Martinez AA et al. Brachytherapy from radium to optimization. Nucletron International, Veenendall 1994; 319-330.
4. Luini A, Gatti G, Zurrida S et al. The evolution of the conservative approach to breast cancer. Breast 2007; 16: 120-129.
5. Fijuth J. Brachytherapy in breast cancer. J Contemp Brachyther 2009: 1: 117-120.
6. Hoped JT, Wazer DE. A comparison of brachytherapy techniques for partial breast irradiation. Brachytherapy 2012; 11: 163-175.
7. Skowronnek J, Chichel A. Brachytherapy in breast cancer: an effective alternative. Prz Menopauzalny 2014: 13: 48-55.
8. ICRU: Report 38: Dose and volume specifications for reporting Interstitial Therapy. ICRU, Bethesda 1997.
9. Hennesquin C, Mazeron JF, Chotin G. How to use Paris system in the year 2001? Radiother Oncol 2001; 58: 5-6.
10. Van Limbergen E. Indications and technical aspects of brachytherapy in breast conserving treatment of breast cancer. Brachytherapy 2003; 7: 107-120.
11. Major T, Fodor J, Takácsi-Nagy Z et al. Evaluation of HDR interstitial breast implants planned by conventional and op-
timized CT-based dosimetry systems with respect to dose homogeneity and conformality. Strahlenther Onkol 2005; 181: 89-96.

12. Major T, Fröhlich G, Polgar C. Assessment of dose homogeneity in conformal interstitial breast brachytherapy with special respect to ICRU recommendations. J Contemp Brachytherapy 2011; 3: 150-155.

13. Aristhei C, Tarducci R, Palumbo I et al. Computed tomography for excision cavity localization and 3D-treatment planning in partial breast irradiation with high-dose-rate interstitial brachytherapy. Radiother Oncol 2009; 90: 43-47.

14. Vicini FA, Kestin LL, Edmundson GK et al. Dose-volume analysis for quality assurance of interstitial brachytherapy for breast cancer. Int Radiat Oncol Biol Phys 1999; 45: 803-810.

15. Kestin LL, Jaffray DA, Edmundson GK et al. Improving the dosimetric coverage of interstitial high dose rate breast implants. Int J Radiat Oncol Biol Phys 2000; 46: 35-43.

16. Das RK, Patel R, Shah H et al. 3D CT-based high-dose-rate breast brachytherapy implants; treatment planning and quality assurance. Int J Radiat Oncol Biol Phys 2004; 59: 1224-1228.

17. Wazer DE, Kramer B, Schmid C et al. Factors determine outcome in patients treated with interstitial implantation as a radiation boost for breast conservation therapy. Int J Radiat Oncol Biol Phys 1997; 39: 381-393.

18. Major T, Fröhlich G, Lovey K et al. Dosimetric experience with accelerated partial breast irradiation using image-guided interstitial brachytherapy. Radiother Oncol 2009; 90: 48-50.

19. Cholewka A, Słag M, Słosarek K et al. Comparison of 2D and 3D-guided implantation in accelerated partial breast irradiation (APBI). J Contemp Brachytherapy 2009; 1: 207-210.

20. Tang J, Wee Tan P, Yangling Koh V et al. Multi-catheter interstitial accelerated partial breast irradiation – tips and tricks for a good insertion. J Contemp Brachytherapy 2014; 6: 85-90.

21. Gutiérrez C, Najari D, Martínez E et al. The use of an interstitial boost in the conservative treatment of breast cancer: how to perform it routinely in radiotherapy department. J Contemp Brachytherapy 2015; 6: 397-403.

22. Skowronek J, Wawrzyniak-Hojczyk M, Ambrochowicz K. Brachytherapy in accelerated partial breast irradiation (APBI) – review of treatment methods. J Contemp Brachytherapy 2012; 4: 152-164.

23. Gruszczynska E, Dabkowski M, Kawczyńska M et al. Dosimetric comparison between 2D dose point and 3D CT-based volume optimization in breast boost HDR brachytherapy. World Congress of Brachytherapy, Barcelona, 2012 (Abstract).

24. Cholewka A, Słag M, Bialas B et al. The importance of the implant quality in APBI – Gliwice experience. Dosimetric evaluation. J Contemp Brachytherapy 2013; 5: 227-231.

25. Potter R, Van Limbergen E, Wambersie A. Reporting in brachytherapy: dose and volume specification. In: Gerbaulet A, Potter R, Mazeron JJ, Meertens H, Van Limbergen E (eds.). The GEC ESTRO Handbook of Brachytherapy. ESTRO, Brussels 2002: 155-215.

26. Shah Ch, Vicini F, Wazer D et al. The American Brachytherapy Society consensus statement for accredited partial breast irradiation. Brachytherapy 2013; 12: 267-277.

27. Strynad V, Hannoun-Levi JM, Guinot JL et al. Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery. Radiother Oncol 2015; 115: 342-348.

28. Resch A, Pötter R, Van Limbergen E et al. Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer. Radiother Oncol 2002; 63: 47-58.